Nitroglycerin lingual spray - Seelos Therapeutics
Alternative Names: NitroMistLatest Information Update: 02 Oct 2021
At a glance
- Originator NovaDel Pharma
- Developer Mist Pharmaceuticals
- Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
- Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Angina pectoris
Most Recent Events
- 25 Jan 2019 Seelos Therapeutics merged with Apricus Biosciences to form Seelos Therapeutics
- 19 Nov 2013 Mist Pharmaceuticals acquires all patents, trademarks and license agreements related to nitroglycerin lingual spray
- 08 Apr 2013 Nitroglycerin lingual spray - NovaDel Pharma is available for purchase as of 08 Apr 2013. http://www.novadel.com/